Biological therapy uses the body's own immune system to target and fight breast cancer cells.
One such antibody is Herceptin, a monoclonal (meaning single) antibody. An antibody is a protein made by the body's own immune system. Herceptin is a manmade antibody that can work only if the woman carries and overexpresses the HER2 protein in those tumor cells. About 25% of breast cancer patients carry this gene and are considered HER2 positive. Your doctor should check this on your breastbiopsy or on the tumor removed during surgery.
By Hallie Levine Sklar
Young Women Who Get Breast Cancer Are More Likely to
Women who are diagnosed with breast cancer before age 40 have slightly
poorer prognoses than older women: Their five-year survival rate is about 82
percent, compared with 85 percent among women ages 40 to 74, according to the
American Cancer Society (ACS). Why? "Younger women are more likely to have
more aggressive tumors," explains Lisa Carey, M.D., medical director of the
University of North Carolina...
Herceptin is the first-line treatment of HER2-positive metastatic breast cancer in combination with chemotherapy drugs. Herceptin may also be used alone, indefinitely, for HER2- positive metastatic breast cancer.
Perjeta (pertuzumab) is another monoclonal antibody approved for treatment of HER2-positive metastatic breast cancer or for patients who need neo-adjuvant treatment (treatment before surgery). It is approved for use in combination with Herceptin and the chemotherapy Taxotere.
Another drug for patients with HER2 positive disease is Tykerb (lapatinib). It works in HER2-positive patients when Herceptin is no longer effective. It is used in combination with Xeloda, Femara, or Herceptin.
Kadcyla (ado-trastuzumab emtansine) is a drug used in patients who have metastatic disease and have already taken Herceptin and a class of chemotherapy drugs called taxanes, which are commonly used to treat breast cancer. These drugs may have been used together or separately.
Other types of antibodies are being researched to fight cancer and include:
Angiogenesis inhibitors. These antibodies prevent the growth of new blood vessels, cutting off the supply of oxygen and nutrients to cancer cells. However, the only such drug used for breast cancer, bevacizumab, lost its FDA approval for breast cancer because the drug's risks outweighed its benefits and it didn't improve the overall survival of breast cancer patients.
Signal transduction inhibitors. These antibodies block signals inside the cancer cell that helps the cells divide, stopping the cancer from growing. They are currently being studied to see if they're effective.
Before treatment begins, print out these Questions to Ask to help you better understand your care.